Neuroinflammation and treatment resistance in major depressive disorder
Frontiers in Pharmacology · 08.06.2026 · 17
DOI: 10.3389/fphar.2026.1838472 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 08.06.2026. Verfasst von Shingo Miyata und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Molecular Brain Science, Research Institute of Traditional Asian Medicine, Kindai University, Sakai, Japan. Die Arbeit nennt 149 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Major depressive disorder (MDD) is increasingly recognized as a multi-system disease that extends beyond neurotransmitter dysregulation. Treatment-resistant depression (TRD), which affects approximately one-third of patients who do not achieve remission with monoaminergic antidepressants, poses a significant global challenge because of its association with a heightened risk of suicide and impaired social functioning. Low-grade chronic inflammation, a hallmark of TRD, increases blood-brain barrier (BBB) permeability. These inflammatory signals can affect the central nervous system, induce alterations in neural circuits, and contribute to depressive symptom development. A shift is necessary in the treatment of patients with TRD, moving from conventional symptom-based diagnosis to personalized medicine based on biological subtypes using inflammatory markers. In the future, complex interventions that facilitate a restorative immune environment in the brain—such as enhancing the M2 phenotype and restoring homeostasis in the nervous, immune, and endocrine systems—are anticipated to become central to next-generation antidepressant therapies. This review provides a comprehensive overview of the molecular and cellular mechanisms through which peripheral and central inflammation contribute to the pathophysiology of TRD.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Molecular Brain Science, Research Institute of Traditional Asian Medicine, Kindai University, Sakai, Japan.
Zitieren
APA
Miyata, S., Ishino, Y., & Shimizu, S. (2026). Neuroinflammation and treatment resistance in major depressive disorder. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1838472
Vancouver
Miyata S, Ishino Y, Shimizu S. Neuroinflammation and treatment resistance in major depressive disorder. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1838472
BibTeX
@article{Miyata2026,
author = {Miyata, Shingo and Ishino, Yugo and Shimizu, Shoko},
title = {Neuroinflammation and treatment resistance in major depressive disorder},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1838472}
}
EUVIMED